A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

NCT06719011 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: NNC0174-1213 A
DRUG: Cagrilintide B
DRUG: Placebo A (NNC0174 1213 A)

Sponsor

Novo Nordisk A/S